$0.58
-0.22 (-27.50%)
NeurogesX, Inc. (NASDAQ:NGSX)
CAPS Rating:
A biopharmaceutical company, which focused on developing and commercializing novel pain management therapies.
A biopharmaceutical company, which focused on developing and commercializing novel pain management therapies.